Japanese maker of OTC eye drops, pharmaceuticals and skincare, known for the Hada Labo skincare brand.
Japanese maker of OTC eye drops, pharmaceuticals and skincare, known for the Hada Labo skincare brand.
Sells over-the-counter eye drops and skincare through drugstores and retailers, with brands advertised heavily to keep shelf space. Its portfolio also includes the Mentholatum and Obagi brands, which give it a sizeable business outside Japan, and Hada Labo is sold widely across Asia.
In one line: Japan's Bausch + Lomb, plus a skincare business like a smaller L'Oreal.
Moat: narrow (brand, IP / patents). Leading eye-drop brand recognition and Hada Labo skincare formulation IP with global reach.
Headquarters: Osaka, Japan · Founded: 1899 · Employees: 9,292
Size Rohto Pharmaceutical (4527.T) is a Japan Consumer Staples company (Household/Personal Care) with a market value of $3.87B, the 300th largest of 1,370 Japan companies the cockpit tracks. Shares closed at ¥2,643 on 18 Nov 2026.
Performance Over six months the shares gained 8.4%, against -2.5% for the median peer and -1.4% for the Japan market (cap-weighted) — 9th highest of 21 in its peer set.
Growth Revenue grew 7.4% over the last twelve months (peer median +5.2%); the operating margin is 11.9% (peer median 13.8%).
Valuation It trades at 16.5× forward earnings against a peer median of 19.9× (9th cheapest of 20).
Price implies For today's price to make sense, revenue must grow about -3% a year for seven years (Req g). Recent delivered growth is +14%, so the hurdle is -17 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 4.2 points above its cost of capital (5.0% WACC).
Next results Next results expected around 12 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ¥358B | ¥344B | ¥309B | ¥271B | ¥239B |
| Revenue growth | — | +11% | +14% | +13% | — |
| Gross profit | ¥199B | ¥183B | ¥169B | ¥155B | ¥135B |
| EBITDA | ¥60.9B | ¥58.1B | ¥51.1B | ¥48.9B | ¥41.3B |
| Net income | ¥33.1B | ¥34.2B | ¥30.8B | ¥30.9B | ¥26.4B |
| Free cash flow | n/a | ¥36.3B | ¥27.8B | ¥26.3B | ¥22.5B |
| Capital expenditure | n/a | ¥26.3B | ¥10.6B | ¥8.91B | ¥9.91B |
| Total debt | ¥49.0B | ¥64.2B | ¥61.2B | ¥12.8B | ¥13.6B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Rohto Pharmaceutical 4527.T | $3.87B | +8% | +7% | 12% | 16.5× | -2.8% |
| Kobayashi Pharmaceutical 4967.T | $3.25B | +20% | +2% | 6% | 48.7× | 18.0% |
| L'Oreal OR.PA | $259B | +20% | +3% | 21% | 32.3× | 18.1% |
| Santen Pharmaceutical 4536.T | $4.14B | +10% | +2% | 16% | 16.7× | -5.0% |
| Lion 4912.T | $3.85B | +44% | +6% | 8% | 24.3× | 0.9% |
| Shiseido 4911.T | $10.8B | +47% | +6% | 6% | 35.1× | 12.7% |
| KOSE 4922.T | $2.16B | +16% | +4% | 5% | 29.9× | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 4527.T | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -9.2% | -0.5% | 5th lowest of 21 |
| 6-month return | +8.4% | -2.5% | 9th highest of 21 |
| Distance from 52-week high | -15.3% | -21.6% | 9th highest of 21 |
| Revenue growth (TTM) | +7.4% | +5.2% | 10th highest of 21 |
| Operating margin | 11.9% | 13.8% | 9th lowest of 21 |
| Forward P/E | 16.5× | 19.9× | 9th cheapest of 20 |
| Growth the price implies (Req g, 7 yrs) | -2.8% | 3.9% | 6th least demanding of 19 |
| Growth delivered (Del g) | +13.7% | +6.0% | 8th highest of 19 |
| Hurdle (Req g minus delivered) | -16.5 pp | -2.6 pp | 5th least demanding of 19 |
| ROIC minus cost of capital | +4.2 pp | +5.3 pp | 9th lowest of 19 |
| EV / EBITDA | 9.9× | 13.2× | 5th cheapest of 18 |
| Net debt / EBITDA | -0.6× | -0.6× | 9th most indebted of 19 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Rohto Pharmaceutical 4527.T | Japan | $3.87B | +8% | +7% | 12% | 16.5× | -2.8% | +13.7% |
| Lion 4912.T | Japan | $3.85B | +44% | +6% | 8% | 24.3× | 0.9% | +3.5% |
| Coty COTY | United States | $3.71B | +116% | 0% | 5% | 13.5× | 9.8% | +4.6% |
| Interparfums IPAR | United States | $4.28B | +48% | +3% | 18% | 28.4× | 10.5% | +22.5% |
| Hengan Int'l 1044.HK | Hong Kong | $3.27B | -12% | +2% | 11% | 9.1× | -8.2% | -0.1% |
| Kobayashi Pharmaceutical 4967.T | Japan | $3.25B | +20% | +2% | 6% | 48.7× | 18.0% | +1.9% |
| Mao Geping Cosmetics 1318.HK | Hong Kong | $4.67B | -8% | +32% | 31% | 14.3× | 4.1% | +41.1% |
| Colgate-Palmolive (India) COLPAL.NS | India | $4.91B | -23% | +9% | 28% | 32.4× | 31.1% | +4.5% |
| Proya Cosmetics 603605.SS | China | $2.87B | -13% | +2% | 13% | 10.9× | -5.3% | +23.1% |
| Cupid CUPID.NS | India | $5.22B | +218% | +125% | 33% | n/a | n/a | n/a |
| Reynolds Consumer Products REYN | United States | $5.28B | +15% | +2% | 14% | 15.3× | 0.8% | +2.7% |
| LG H&h 051900.KS | South Korea | $2.81B | -14% | -3% | 3% | 23.1× | -4.6% | -4.1% |
| Gillette India GILLETTE.NS | India | $2.53B | -5% | +8% | 28% | 37.1× | 14.9% | +13.0% |
| Winner Medical 300888.SZ | China | $2.53B | -6% | +4% | 11% | 19.9× | -5.2% | -2.6% |
| Cosmax 192820.KS | South Korea | $2.51B | +53% | +25% | 8% | 18.8× | n/a | n/a |
| Amorepacific 090430.KS | South Korea | $6.01B | 0% | +10% | 9% | 24.4× | 3.6% | -0.8% |
| Giant Biogene 2367.HK | Hong Kong | $2.47B | -32% | -10% | 32% | 8.6× | -10.7% | +34.9% |
| Procter & Gamble Hygiene & Health Care PGHH.NS | India | $2.37B | -30% | -2% | 24% | 27.0× | 21.2% | +7.4% |
| APR 278470.KS | South Korea | $6.66B | -45% | +119% | 24% | 16.2× | -2.3% | +47.3% |
| e.l.f. Beauty ELF | United States | $6.73B | +124% | +40% | 14% | 34.3× | 24.1% | +38.8% |
| Softcare 2698.HK | Hong Kong | $2.20B | +5% | +25% | 25% | 14.4× | 9.1% | +20.9% |